Connect with us

Technology

IDBS and Alchemi partner to accelerate biopharma regulatory filings with compliant AI agents

Published

on

NEW YORK and WOKING, England, June 16, 2026 /PRNewswire/ — IDBS, a Danaher company and leading provider of cloud software for biopharma, and Alchemi, a leading applied AI company serving the world’s largest pharma and biotech development teams, today announced a partnership connecting AI agents to data captured and contextualized in the IDBS Polar platform across the drug development lifecycle.

Preparing regulatory filings remains one of biopharma’s most persistent bottlenecks. CMC teams spend months assembling data, drafting reports and reconstructing process histories, while current AI tools often break the compliance chain by pulling data out of validated systems.

Connecting Alchemi’s purpose-built agents to Polar’s trusted, AI-ready data foundation keeps validated data traceable and auditable. CMC technical reports, clinical study reports and submission dossiers can be drafted faster and routed through human-in-the-loop workflows for review and sign-off, maintaining compliance. According to Alchemi, in customer deployments across biopharma, teams have produced documents of this type up to 70% faster using its agents.

IDBS Polar powers the Lab Loop—from experiment execution, through data aggregation, to insights that drive decisions. By capturing structured, contextualized data at the point of creation within a single governed backbone, Polar delivers the data foundation that makes agentic AI viable in regulated environments.

Alchemi’s agents draw on Polar’s governed data to draft these reports and dossiers, then route each draft to a scientist for review and sign-off. Each human and AI action is captured in a 21 CFR Part 11 audit trail, so the work stays compliant from source to submission.

AI agents are only as good as the data they act on. This partnership ensures biopharma teams get both: governed data from Polar and purpose-built intelligence from Alchemi.

“A regulatory filing that takes a team weeks, our agents draft in minutes, at submission-ready quality, with the compliance trail intact, because they work straight from governed data in Polar. That’s the difference between AI you can demo and AI you can take to submission,” said Anuj Chadha, Co-Founder, Alchemi.

“Our mission is to accelerate life-changing therapies to patients, and as part of Danaher, that means turning ideas into impact with speed and certainty. IDBS delivers a governed data backbone that makes AI-ready data available across the biopharma lifecycle. By partnering with Alchemi, we can accelerate critical regulatory milestones using high-quality, compliant AI agents,” said Pietro Forgione, General Manager, IDBS.

About IDBS

IDBS, a Danaher company, helps biopharma organizations turn scientific data into trusted insight that accelerates innovation and improves patient outcomes. A long-term partner to 75% of the top 20 global biopharma companies¹, we bring 35 years of scientific informatics expertise to deliver cloud software and services that connect data, workflows and teams across the product lifecycle from R&D through manufacturing.

The IDBS Polar platform powers the Lab Loop, from experiment execution through data aggregation to the insights that drive decisions. By capturing structured, contextualized data at the point of creation, Polar delivers an AI-ready data foundation for advanced analytics and agentic AI across both GxP and non-GxP environments. IDBS PIMS extends this capability into manufacturing with process insight for batch monitoring, continued process verification and regulatory reporting support.

As part of Danaher, IDBS combines deep domain expertise with continuous innovation to help customers solve complex scientific challenges and turn insight into impact at global scale.

Visit idbs.com to learn more about IDBS.

IDBS is proud to be part of Danaher. Visit www.Danaher.com to learn more about Danaher, a leading life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health.

Rank measured by Market Cap, Q2 2026.

About Alchemi

Alchemi builds AI agents that accelerate drug development, compressing work that takes scientists weeks into minutes. Its agents work across the development lifecycle, from non-clinical and clinical through CMC, regulatory submissions and post-marketing. They draft and review documents, analyze and quality-check data, and streamline safety and manufacturing workflows, all from governed data and routed through human review.

Each agent is built by Alchemi scientists and AI engineers working side by side and tailored to each customer’s unique workflows and standards, rather than a one-size-fits-all approach. Every AI and human action is captured in full 21 CFR Part 11 audit trails, so speed never breaks the compliance chain.

Founded in 2024 and headquartered in New York, Alchemi will deliver at least 3,000 studies this year with top-five global CROs, large pharma and biotech. Alchemi is on a mission to get life-changing therapies to patients faster.

Learn more at www.alchemi.bio.

MEDIA ENQUIRIES

IDBS:
e |  mediaenquiries@idbs.com 

Alchemi:

 e | contact@alchemi.bio

View original content to download multimedia:https://www.prnewswire.com/news-releases/idbs-and-alchemi-partner-to-accelerate-biopharma-regulatory-filings-with-compliant-ai-agents-302801591.html

SOURCE IDBS

Continue Reading

Technology

PHONO Marks 20th Anniversary and Secures New Orders at RE+ 2026

Published

on

By

LAS VEGAS, Nov. 21, 2026 /PRNewswire/ — PHONO showcased its diverse solar and energy storage solutions at RE+ 2026, held November 17–19 in Las Vegas, highlighting its latest offerings for residential, commercial, solar carport, and utility-scale applications. Marking its 20th anniversary, PHONO recognized long-standing U.S. customers and explored new opportunities for collaboration. The company also secured 150 MW in new orders during the event, underscoring its continued business momentum and commitment to the U.S. solar market. 

As the U.S. solar market continues to evolve, developers and project owners are placing greater emphasis on supply chain transparency, regulatory compliance, and project economics. In response, PHONO is leveraging its global supply chain capabilities and diversified product portfolio to deliver reliable, cost-effective solutions tailored to the needs of the U.S. market.

Solutions for Diverse Application Scenarios

PHONO showcased a diverse portfolio of solar and energy storage solutions, including the Draco Series 450W True Black module for residential rooftops and the Twinplus Series 550W bifacial module for commercial and industrial applications, featuring a lightweight transparent backsheet and up to 76.8% U.S. domestic content, while the Draco Series 730W bifacial module is designed for high energy yield in utility-scale projects. PHONO also presented its 261 kWh and 932 kWh outdoor energy storage systems, offering flexible solutions for diverse energy needs.

Industry Insights and Market Perspectives

On November 17, PHONO hosted an expert speaker session at its booth, featuring representatives from BloombergNEF, RETC, and Kiwa PVEL. The discussions covered the 2027 U.S. solar market outlook, evolving policies, and PV module reliability, offering valuable market perspectives and technical insights.

Built on Trust, Growing Together

As PHONO celebrated its 20th anniversary, representatives from its eight leading U.S. customers visited the booth to discuss future cooperation. General Manager Zhong Zaifeng presented anniversary awards to long-standing partners in recognition of their continued trust and support.

Despite a challenging market environment, orders from the U.S. market grew approximately 200% year over year in 2026. During RE+ 2026, the company secured 150 MW in new orders, with over 500 MW in its sales pipeline, reflecting continued business momentum in the U.S. market. The awards and new agreements highlighted PHONO’s long-term partnerships and continued commitment to the U.S. market.

Looking ahead, PHONO remains committed to strengthening its product innovation, global supply chain, and local services while building lasting partnerships to support the clean energy transition.

View original content to download multimedia:https://www.prnewswire.com/news-releases/phono-marks-20th-anniversary-and-secures-new-orders-at-re-2026-302947598.html

SOURCE PHONO

Continue Reading

Technology

A Seattle Startup Brings Your Pet to Life on Your Phone and Laptop With the Avatar Mirroring Their Every Move in Real Time

Published

on

By

The pet AI startup will demonstrate PettiLive! at CES 2027.

SEATTLE, Nov. 21, 2026 /PRNewswire/ — PettiChat, the Seattle-based pet AI startup behind the world’s first real-time AI pet translator, today announced the launch of PettiLive!, a digital version of each pet that lives in the PettiChat app and on the computer, mirroring the pet’s real life as it happens.

What is PettiLive!

PettiLive! is a digital twin of your pet. Your pet wears a small PettiChat device that tracks what it does throughout the day — running, walking, standing, eating, sleeping, jumping, cleaning itself, and calling out. PettiLive! brings those behaviors to life as a digital pet on your screen, mirroring them in real time. When your pet naps, PettiLive! naps. When your pet runs across the room, PettiLive! runs too. Every movement is driven by your pet’s actual behavior. It is your own pet — its real life, brought into a digital presence.

Because PettiLive! is built around your pet’s real behavior, every digital twin is unique. It continuously learns your pet’s habits: the longer your pet wears the device, the more PettiLive! behaves like your pet. Open the app to see what your pet is doing right now and how its day is unfolding — including activity, meals, rest, and sleep, all measured against its own normal patterns. Whether you are at work, traveling, or simply in the next room, your pet’s daily life is right there on your screen.

PettiChat’s vision: the AI gateway for pets

PettiChat is building the AI gateway for pets, powered by its own pet AI model, PettiWorld. Translation is the first feature PettiChat delivers.

But the vision extends beyond translation: Pet Wellness, built around the pet itself. By tracking eating, playing, sleeping, and daily activity over time, Pet Wellness aims to surface meaningful changes in routines and behavior that owners should pay attention to. PettiLive! is a step toward that vision. The same always-on record of a pet’s life that powers PettiLive! also lays the foundation for longitudinal pet wellness.

One model: PettiWorld

One model powers both experiences. PettiWorld, PettiChat’s self-developed multimodal model for pets, translates pet vocalizations and behaviors into human language while also powering PettiLive!. Trained on 60M+ behavior data points and 10M+ vocalization data points, the model continues to improve — allowing both translation and PettiLive! to get better after launch.

“Owners have always wondered what their pets’ days look like when they are not there,” said Anodime Wen, co-founder of PettiChat. “A camera shows you a room; a tracker shows you a dot. PettiLive! shows you your pet, living its day. That is what it means to build the future of pet care.”

Momentum: from Kickstarter to 20,000 homes — and screens everywhere

Founded in January 2026, PettiChat launched on Kickstarter at the end of April 2026, selling nearly 1,000 units and raising $150K. Since then, more than 20,000 units have reached homes across 120+ countries. PettiChat has also generated more than 500 million impressions on social media, all organic — including individual pet videos that reached 8.1 million views on Instagram and a Polymarket post on X that received 12.2 million views.

PettiLive! is now open to all PettiChat users through the PettiChat app, with the computer version to follow in a month. The PettiChat device ($179) is available on Amazon and at pettichat.com.

PettiChat will exhibit at CES 2027 in Las Vegas and Global Pet Expo 2027 in Orlando.

About PettiChat

PettiChat is a Seattle-based pet AI startup building the future of pet care, powered by PettiWorld, its self-developed multimodal model for pets. Through a small wearable device and app for dogs and cats, PettiChat combines real-time AI translation, PettiLive!, Pet Wellness, and Hybrid Tracking location.

View original content to download multimedia:https://www.prnewswire.com/news-releases/a-seattle-startup-brings-your-pet-to-life-on-your-phone-and-laptop-with-the-avatar-mirroring-their-every-move-in-real-time-302947597.html

SOURCE PettiChat

Continue Reading

Technology

How to Go 2x Long Anthropic (ANT): Leverage Shares by Themes Explains ANUU, the 2x Leveraged Anthropic ETF Launching Monday

Published

on

By

Following Anthropic’s $83-per-share IPO pricing and Nasdaq trading debut at $111.50-per-share on November 19, 2026, Leverage Shares by Themes outlines how investors can gain long exposure to Anthropic stock (ANT), and where its planned 2X Long Anthropic ETF (ANUU) fits into the investment landscape.

GREENWICH, Conn., Nov. 21, 2026 /PRNewswire/ — Leverage Shares by Themes today published a step-by-step guide for investors looking to invest in Anthropic stock following the company’s highly anticipated initial public offering. Anthropic, PBC priced its IPO at $83.00 per share on November 18, 2026, above its initially proposed range of $70 to $78, with the offering totaling approximately $81.3 billion. The company’s Class A common stock began trading on Nasdaq under the ticker ANT on November 19, opening at $111.50 per share. With Anthropic now publicly traded, investors can purchase shares through brokerage accounts, while those seeking leveraged exposure can explore the planned Leverage Shares 2X Long Anthropic Daily ETF (ANUU).

How to Buy Anthropic Stock (ANT) Now That It Is Trading on Nasdaq
Following its IPO on November 19, 2026, investors can buy Anthropic (ANT) shares through a brokerage account that offers Nasdaq-listed stocks.

Step 1: Find Anthropic Stock (ANT) Through Your Brokerage

Search for Anthropic under the ticker ANT in your brokerage account. Investors no longer need to request an IPO allocation, as shares are now available for purchase on the open market during regular trading hours.

Step 2: Check the Current Share Price

Anthropic’s market price may differ significantly from its $83.00 IPO price and can fluctuate throughout the trading day. Review the latest ANT share price before placing an order.

Step 3: Choose How to Buy ANT Shares

Investors can place a market order to buy at the prevailing market price or use a limit order to specify the maximum price they are willing to pay. Given the potential volatility of newly listed stocks, investors should consider the risks of each order type before trading.

Can You Get 2X Long Exposure to Anthropic Stock?
Yes, once it launches: the Leverage Shares 2X Long Anthropic Daily ETF (ANUU) will seek daily investment results, before fees and expenses, corresponding to 200% (2X) of the daily performance of Anthropic common stock.

ANUU is not a way to buy into the IPO itself. The Fund does not take part in the offering and does not hold Anthropic shares. It is designed for knowledgeable investors who want to take a bullish daily view on Anthropic and who monitor their positions actively. Investors with a bearish daily view can use ANDD (2X short) or ANSS (1X short) once they launch.

ANUU, ANDD and ANSS are not yet trading. Their first trading date on Cboe is this coming Monday, November 23, 2026.

Ticker

ETF Name

Underlying
Asset

Exchange

Expense
Ratio

ANUU

Leverage Shares 2X Long Anthropic Daily ETF

Anthropic

Cboe

0.75 %

ANDD

Leverage Shares 2X Short Anthropic Daily ETF

Anthropic

Cboe

0.75 %

ANSS

Leverage Shares 1X Short Anthropic Daily ETF

Anthropic

Cboe

0.99 %

“Most of the questions we are getting this week are practical ones: what the ticker is, when the stock opens and how to buy it,” said Paul Marino, Chief Revenue Officer, Themes ETFs. “We want investors to have clear answers first, and to understand that ANUU is a daily 2X tool for active traders, not a substitute for owning Anthropic shares.”

Frequently Asked Questions

What Is Anthropic’s Stock Ticker?
Anthropic’s Class A common stock is expected to trade on the Nasdaq Global Select Market under the ticker ANT. ANUU, ANDD and ANSS are Leverage Shares ETF tickers, not Anthropic’s.

Is ANUU the Same as Buying Anthropic Stock?
No. ANUU will seek 2X the daily move of Anthropic stock, before fees and expenses. It does not give its investors Anthropic shares or shareholder voting rights, and its returns over periods longer than one day can differ significantly from 2X the stock’s return.

For more on how the three ETFs work, see the Leverage Shares research team’s guide, Anthropic Leveraged ETFs Explained: Long And Short 

Fund pages: 2X Long Anthropic ETF (ANUU) | 2X Short Anthropic ETF (ANDD) | 1X Short Anthropic ETF (ANSS)

About Themes ETFs

Themes ETFs is a provider of thematic and single-stock leveraged ETFs, focused on delivering innovative, cost-efficient investment tools that allow investors to access the companies and trends shaping the future. Through its Leverage Shares platform, Themes ETFs offers daily leveraged and inverse ETF strategies designed for sophisticated investors and active traders.

For more information, visit www.themesetfs.com and www.leverageshares.com.

INVESTMENT INVOLVES SIGNIFICANT RISK. Funds do not invest directly in the underlying stock. As with any investment, there is a risk that you could lose all or a portion of your investment in the Funds.

An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about Themes ETFs. To obtain a Fund’s prospectus and summary prospectus call 866-584-3637. A Fund’s prospectus and summary prospectus should be read carefully before investing.

Newly launched Funds have risks associated with a limited operating history.

Because of daily rebalancing and the compounding of each day’s return over time, the return of a Fund for periods longer than a single day will be the result of each day’s returns compounded over the period, which will very likely differ from the stated multiple or inverse multiple of the return of the underlying stock over the same period. The Funds are not suitable for all investors. The Funds are designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged or inverse investment results, understand the risks associated with the use of leverage and inverse exposure, as applicable, and are willing to monitor their portfolios frequently. The Funds are not intended to be used by, and are not appropriate for, investors who do not intend to actively monitor and manage their portfolios.

Under the Investment Advisory Agreement between the Adviser and the Trust, on behalf of the Funds (the “Investment Advisory Agreement”), the Adviser has agreed to pay all expenses of the Funds, except for the fee paid to the Adviser pursuant to the Investment Advisory Agreement, interest charges on any borrowings, taxes, brokerage commissions and other expenses incurred in placing orders for the purchase and sale of securities and other investment instruments, acquired fund fees and expenses, accrued deferred tax liability, extraordinary expenses, and distribution (12b-1) fees and expenses.

Past performance does not guarantee future results.

INVESTMENT RISKS: Investing in the Funds involves a high degree of risk. As with any investment, there is a risk that you could lose all or a portion of your investment in the Funds.

Investment in leveraged and inverse products may be subject to higher volatility. The Funds do not directly invest in the underlying stock. An investment in a Fund involves risk, including the possible loss of principal. The Funds are non-diversified and include risks associated with concentrating investments in a particular industry, sector, or geographic region, which can result in increased volatility. The use of derivatives such as futures contracts and swaps is subject to market risks that may cause their price to fluctuate over time.

Risks of the Funds include effects of Compounding and Market Volatility Risk, Inverse Risk, Market Risk, Counterparty Risk, Rebalancing Risk, IntraDay Investment Risk, Daily Index Correlation Risk, Other Investment Companies (including ETFs) Risk, and risks specific to the securities of the Underlying Stock and the sector in which it operates. These and other risks can be found in the prospectus.

For periods longer than a single day, the Funds may lose money even if Anthropic’s stock price remains flat or moves in a direction consistent with a Fund’s investment objective. An investor could lose the full principal value of their investment in the Leverage Shares 2x Long Anthropic Daily ETF (ANUU) if Anthropic’s stock price declines by more than 50% in a single trading day, or in the Leverage Shares 2x Short Anthropic Daily ETF (ANDD) if Anthropic’s stock price increases by more than 50% in a single trading day. The Leverage Shares 1x Short Anthropic Daily ETF (ANSS) also carries the risk of substantial or total loss if Anthropic’s stock price rises significantly.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (NBBO) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. Indices are unmanaged and do not include the effect of fees, expenses, or sales charges. One cannot invest directly in an index.

This information is not an offer to sell or a solicitation of an offer to buy shares of any Funds to any person in any jurisdiction in which an offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction.

Themes Management Company LLC serves as an adviser to the Themes ETFs Trust. The Funds are distributed by ALPS Distributors, Inc. (1290 Broadway, Suite 1000, Denver, Colorado 80203). ALPS is not affiliated with Anthropic or any other mentioned entity. Client brokerage services are not offered by ALPS. Please see third-party sites for more information about any mentioned services.

Themes ETFs are not sponsored, endorsed, issued, sold, or promoted by Anthropic, nor does Anthropic make any representations regarding the advisability of investing in Themes ETFs. Neither ALPS Distributors, Inc., Themes Management Company LLC nor Themes ETFs are affiliated with Anthropic.

Themes Management Company LLC and Leverage Shares are affiliates that are under common control. Themes Management Company LLC and Leverage Shares have entered into a licensing agreement in which Leverage Shares licenses the trademark LEVERAGE SHARES to Themes Management Company LLC for use in financial services in the United States.

View original content:https://www.prnewswire.com/news-releases/how-to-go-2x-long-anthropic-ant-leverage-shares-by-themes-explains-anuu-the-2x-leveraged-anthropic-etf-launching-monday-302947477.html

SOURCE Themes ETFs

Continue Reading

Trending